Type1diabetes
Conditions
Brief summary
This is a combined phase 1 and 2 study in 66 subjects, male or female, between 7-21 years of age that have recently (\< 6 months) been diagnosed with type 1 diabetes. The first phase 1 part of the study includes six subjects openly receiving allogeneic Wharton's jelly derived mesenchymal stromal cells as the Advanced Therapy Medicinal Product (ATMP) Protrans, three each in the age ranges 7-11 and 12-18.The second part is a randomized, double-blinded placebo-controlled phase 2 study in parallel design comparing allogeneic Wharton's jelly derived mesenchymal stromal cells treatment (as Protrans) to placebo in children and adolescent subjects (7-21 years of age) diagnosed with type 1 diabetes, The primary objectives of this study will be to investigate the safety, tolerance and efficacy after an allogieneic infusion of Wharton's jelly derived mesenchymal stromal cells.
Interventions
BIOLOGICALthe ATMP Protrans
Protrans consists of Wharton's jelly derived mesenchymal stromal cells
Sponsors
Uppsala University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
7 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
1. Written informed consent for participation of the study (for subjects below 18 years of age also from both caregivers), given before undergoing any study-specific procedures 2. Clinical history compatible with type 1 diabetes diagnosed less than 6 months before enrolment 3. In the first part of the study, six subjects, three between 7-11 and three between 12-18 years of age (both groups inclusive at both ends), will be included. The sixty subjects in the second part of the study are stratified by age (12-21 and 7-11 years, respectively) and randomized to one of two treatment arms (active or placebo), with a 6-month safety delay for the younger stratum. 4. Mentally stable and, in the opinion of the investigator, able to comply with the procedures of the study protocol. 5. Fasting plasma C-peptide concentration \>0.12 nmol/L. 6. Subjects of child-bearing potential must agree to using adequate contraception until one year after the administration of WJMSC/Placebo. Adequate contraception is as follows: 1. oral (except low-dose gestagen (lynestrenol and noretisteron), injectable or implanted hormonal contraceptives. 2. intrauterine device 3. intrauterine system (for example progestin-releasing coil) 4. vasectomized male (with appropriate postvasectomy documentation of the absence of sperm in the ejaculate)
Exclusion criteria
1. Subjects with body weight \>100 kg 2. Subjects with unstable cardiovascular status incl. NYHA class III/IV or symptoms of angina pectoris. 3. Subjects with uncontrolled hypertension (≥160/105 mmHg). 4. Subjects with active on-going infections. 5. Subjects with latent or previous as well as on-going therapy against tuberculosis, or exposed to tuberculosis or has traveled in areas with a high risk of tuberculosis or mycosis within the last 3 months. 6. Subjects with serological evidence of infection with HIV, Treponema pallidum, hepatitis B antigen (subjects with serology consistent with previous vaccination and a history of vaccination are acceptable), or hepatitis C. 7. Subjects with any systemic immune suppressive treatment 8. Subjects with a known demyelinating disease or with symptoms or physical examination findings consistent with possible demyelinating disease. 9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. 10. Subjects with known, or previous, malignancy. 11. Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin. 12. Subjects with GFR \<60 ml/min/1.73 m2 body surface. 13. Subject with any condition or any circumstance that, in the opinion of the investigator, would make it unsafe to undergo treatment with MSC. 14. Known hypersensitivity against any excipients, i.e., dimethyl sulfoxide (DMSO).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety at one year evaluated as adverse events | One year | Safety parameters will be evaluated at each study visit and recorded as adverse events. |
| Safety at five years evaluated as adverse events | Five years | Safety parameters will be evaluated at each study visit and recorded as adverse events. |
| Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test. | One year | Change in C-peptide Area under the curve (AUC) (0-120 min) for mixed meal tolerance test (MMTT) at 12 months following Protrans/Placebo infusion when compared to test performed before the start of treatment (baseline). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Insulin independency | One year | The proportion of study participants independent of insulin at 6 months |
| Low insulin needs | 6 months | The proportion of study participants with daily insulin needs \<0.25 U/kg at 6 months |
| Insulin needs | 6 months | Insulin requirement/kg body weigh at 6 months |
| HbA1c | 6 months | HbA1c at 6 months |
| Time in target | 6 months | Time in target (4-8 mmol/l) as measured by flash glucose monitoring for 14 days at 6 months |
| Time in range | 6 months | Time in target (3.9-10 mmol/l) as measured by flash glucose monitoring for 14 days at 6 months |
| C-peptide | 6 months | Change in C-peptide Area under the curve (AUC) (0-120 min) for mixed meal tolerance test (MMTT) at 6 months following Protrans/Placebo infusion when compared to test performed before the start of treatment (baseline). |
| Change in peak C-peptide | 6 months | Change in peak C-peptide concentration during the first 6 months |
Countries
Sweden
Contacts
PRINCIPAL_INVESTIGATORPer-Ola Carlsson, MD, PhD
Uppsala University Hospital
Outcome results
None listed